[go: up one dir, main page]

WO2007029078A3 - Succinimide and glutarimide derivatives as adrenergic receptor antagonists - Google Patents

Succinimide and glutarimide derivatives as adrenergic receptor antagonists Download PDF

Info

Publication number
WO2007029078A3
WO2007029078A3 PCT/IB2006/002370 IB2006002370W WO2007029078A3 WO 2007029078 A3 WO2007029078 A3 WO 2007029078A3 IB 2006002370 W IB2006002370 W IB 2006002370W WO 2007029078 A3 WO2007029078 A3 WO 2007029078A3
Authority
WO
WIPO (PCT)
Prior art keywords
succinimide
receptor antagonists
adrenergic receptor
bph
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002370
Other languages
French (fr)
Other versions
WO2007029078A2 (en
Inventor
Pakala Kumara Savithru Sarma
Sandeep Y Shelke
K Ashani
Praful Gupta
Arani Pal
Atul Kondaskar
Sankaranarayanan Dharmarajan
Somesh Sharma
Anita Chugh
Atul Tiwari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2007029078A2 publication Critical patent/WO2007029078A2/en
Publication of WO2007029078A3 publication Critical patent/WO2007029078A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to succinimide and glutarimide derivatives having the structure of Formula I, which can be used to treat a disease or disorder mediated through α1a and/or α1d adrenergic receptors. Compounds and pharmaceutical compositions disclosed herein can be used to treat benign prostatic hyperplasia (BPH) and related symptoms thereof. Further, such compounds can be used to treat lower urinary tract symptoms that may or may not be associated with BPH. The present invention also relates to processes to prepare the disclosed compounds, pharmaceutical compositions thereof, and methods of treating BPH or related symptoms thereof.
PCT/IB2006/002370 2005-09-05 2006-08-30 Succinimide and glutarimide derivatives as adrenergic receptor antagonists Ceased WO2007029078A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2371/DEL/2005 2005-09-05
IN2371DE2005 2005-09-05

Publications (2)

Publication Number Publication Date
WO2007029078A2 WO2007029078A2 (en) 2007-03-15
WO2007029078A3 true WO2007029078A3 (en) 2007-07-12

Family

ID=37714265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002370 Ceased WO2007029078A2 (en) 2005-09-05 2006-08-30 Succinimide and glutarimide derivatives as adrenergic receptor antagonists

Country Status (1)

Country Link
WO (1) WO2007029078A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2994457B1 (en) 2013-05-07 2021-01-06 The Regents of the University of California Radiomitigating pharmaceutical formulations
US10525050B2 (en) * 2017-01-06 2020-01-07 Florida A&M University Alkylated tetrahydroisoquinolines for binding to central nervous system receptors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3171839A (en) * 1961-05-18 1965-03-02 Searle & Co 4-alkyl-1-(cyclic imidoalkyl) piperidines
US20010046993A1 (en) * 1999-12-10 2001-11-29 Takafumi Ikeda 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
US6410735B1 (en) * 1997-11-13 2002-06-25 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-y1)-ω-[N-(α,ω-dicarboximido)]-alkanes useful as uro-selective α1-adrenoceptor blockers
WO2003003008A1 (en) * 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
WO2003084928A1 (en) * 2002-04-08 2003-10-16 Ranbaxy Laboratories Limited Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers
WO2005018643A1 (en) * 2003-08-25 2005-03-03 Ranbaxy Laboratories Limited Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3171839A (en) * 1961-05-18 1965-03-02 Searle & Co 4-alkyl-1-(cyclic imidoalkyl) piperidines
US6410735B1 (en) * 1997-11-13 2002-06-25 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-y1)-ω-[N-(α,ω-dicarboximido)]-alkanes useful as uro-selective α1-adrenoceptor blockers
US20010046993A1 (en) * 1999-12-10 2001-11-29 Takafumi Ikeda 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
WO2003003008A1 (en) * 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
WO2003084928A1 (en) * 2002-04-08 2003-10-16 Ranbaxy Laboratories Limited Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers
WO2005018643A1 (en) * 2003-08-25 2005-03-03 Ranbaxy Laboratories Limited Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAO F-L ET AL: "Unique spirocyclopiperazinium salt I: Synthesis and structure-activity relationship of spirocyclopiperazinium salts as analgesics", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 05 MAY 2003 UNITED KINGDOM, vol. 13, no. 9, 5 May 2003 (2003-05-05), pages 1535 - 1537, XP002420363, ISSN: 0960-894X *
NEW J S ET AL: "THE THIENO3,2-CPYRIDINE AND FURO3,2-CPYRIDINE RINGS: NEW PHARMACOPHORES WITH POTENTIAL ANTIPSYCHOTIC ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 32, June 1989 (1989-06-01), pages 1147 - 1156, XP001029837, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2007029078A2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EA200900828A1 (en) COMPOUNDS AND COMPOSITIONS AS AN INHIBITOR ACTIVITY OF THE CANANABINOID RECEPTOR 1
DE602005020655D1 (en) Carboxamide-spirolactam CGRP Receptor Antagonists
WO2006099268A3 (en) Cgrp receptor antagonists
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
NO20092470L (en) Substituted diazepan compounds as orexin receptor antagonists
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2007061763A3 (en) Indole orexin receptor antagonists
GEP20115140B (en) Substituted spirocyclic cgrp receptor antagonists
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
IL182317A0 (en) Cgrp receptor antagonists
EA200970341A1 (en) PYRAZOLINE CONNECTIONS AS ANTAGONISTS OF MINERALOCORTICOID RECEPTORS
WO2005072308A3 (en) Cgrp receptor antagonists
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2007100664A3 (en) Modulators of muscarinic receptors
WO2006105035A3 (en) Muscarinic modulators
DK1551803T3 (en) Azabicyclo derivatives as muscarinic receptor antagonists
WO2007146349A3 (en) Cgrp receptor antagonists
WO2006047196A3 (en) Cgrp receptor antagonists
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
WO2006023852A3 (en) Modulators of muscarinic receptors
WO2007016087A3 (en) Heterocyclic benzodiazepine cgrp receptor antagonists
WO2006058294A3 (en) Modulators of muscarinic receptors
WO2006041830A3 (en) Cgrp receptor antagonists
WO2006120478A3 (en) Quinoline derivatives as neurokinin receptor antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06795374

Country of ref document: EP

Kind code of ref document: A2